6/22/2010 | CV | Market Commentary: Teva series Ds active in trade; Transocean ends lower; Biovail, Lincare better; PPL adds
|
6/21/2010 | CV | Market Commentary: Biovail gains on merger with Valeant; Amgen up on competitor's drug safety; PPL on tap
|
6/21/2010 | HYLM | Valeant to refinance 7 5/8%, 8 3/8% notes as part of Biovail merger
|
11/5/2009 | BK | Biovail repays $75 million of revolving loan debt in third quarter
|
9/21/2009 | SS | Biovail boasts plenty of possibilities in its acquisition pipeline
|
7/14/2009 | SS | Biovail former CEO Eugene Melnyk sells shares, reports 7.6% stake
|
6/10/2009 | CV | Market Commentary: Convertibles mixed in active trade; CMS Energy, Callaway receive quiet receptions; UAL weaker
|
6/9/2009 | BK | Biovail gets $410 million revolver to refinance existing loan
|
6/5/2009 | CV | Market Commentary: Exterran, Western upsize deals, weak stocks mar debuts; Steel Dynamics, Biovail stay afloat
|
6/4/2009 | CV | Market Commentary: Steel Dynamics jumps to 109 on debut; Biovail gains; JetBlue creeps up; more supply on tap
|
6/3/2009 | CV | New Issue: Biovail prices upsized $300 million five-year convertibles to yield 5.375%, up 26%
|
6/3/2009 | CV | Market Commentary: Convertibles quiet as players eye JetBlue, Biovail, Steel Dynamics; Cephalon, Human Genome up
|
6/2/2009 | CV | Biovail to price $200 million five-year convertibles to yield 5.25%-5.75%, up 20%-25%
|
6/2/2009 | CV | Market Commentary: Goldcorp, MasTec trade under par on debuts; JetBlue, Biovail, Steel Dynamics notes to price
|
5/28/2009 | SS | Biovail's nominees elected to board at annual meeting on Thursday
|
5/26/2009 | SS | Biovail, Melnyk end proxy battle; annual meeting to be held Thursday
|
5/19/2009 | SS | Biovail's director nominees recommended by three proxy advisory firms
|
5/15/2009 | SS | Biovail shareholder group says dispute is about reform, not Melnyk
|
5/14/2009 | SS | Biovail's former CEO nominates two for election to company's board
|
4/30/2009 | SS | Biovail urges shareholders to reject former CEO's dissident slate
|
4/27/2009 | SS | Biovail shareholder, founder Melnyk names his two director nominees
|
3/27/2009 | SS | Biovail investor Melnyk sells 3.1 million shares
|
3/17/2009 | SS | Biovail to hold annual meeting, special meeting on May 28
|
2/26/2009 | SS | Market Commentary: Time on NRG's side; House punches Ticketmaster's ticket; Biovail set for acquisitions
|
2/25/2009 | SS | Biovail founder requests special meeting, seeks to make changes to board
|
2/5/2009 | SS | Biovail investor Melnyk sells 2 million shares
|
1/30/2009 | SS | Biovail shareholder Melnyk cuts stake in company to 12.3%
|
12/16/2008 | SS | Biovail shareholder Melnyk reports sale of shares
|
12/12/2008 | SS | Melnyk buys further 2.9% of Biovail, lifting stake to 13.5%
|
12/4/2008 | SS | Genesis Trust reports 5.9% passive stake in Biovail
|
9/23/2008 | BKHY | S&P drops Biovail
|
8/8/2008 | SS | Biovail confirms election of its nominees at reconvened meeting
|
8/6/2008 | SS | Biovail waives proxy voting cut-off
|
7/28/2008 | SS | Melnyk, shareholder group will not contest election of Biovail directors
|
7/21/2008 | SS | Biovail to reconvene annual meeting Aug. 8
|
7/16/2008 | SS | Biovail ordered to reconvene annual meeting; Melnyk to reach out to shareholders
|
7/2/2008 | SS | Melnyk wants court to compel Biovail to hold new annual general meeting
|
6/25/2008 | SS | Biovail and Melnyk continue to spar after vote
|
6/19/2008 | SS | War of words continues in proxy battle between Biovail, Melnyk-led shareholder group
|
6/18/2008 | SS | Biovail, shareholder group cite recommendations from proxy advisory firms in quest for shareholder votes
|
6/17/2008 | SS | Biovail calls Melnyk's latest effort to garner shareholder support a 'desperate publicity stunt'
|
6/16/2008 | SS | Biovail's slate of director nominees backed by RiskMetrics
|
6/10/2008 | SS | Biovail, Melnyk continue battle for shareholder support at annual meeting on June 25
|
6/6/2008 | SS | Biovail shareholder group sponsors web site, seeks proxy votes from employees
|
6/6/2008 | SS | Biovail urges shareholders to elect its nominees, reject former CEO Melnyk's slate, June 25
|
6/4/2008 | SS | Melnyk files proxy circular ahead of Biovail's June 25 annual meeting
|
6/3/2008 | SS | Biovail urges shareholders to reject Melnyk nominees on June 25
|
6/3/2008 | SS | Market Commentary: Smith ropes W-H Energy; Bovail fights Melnyk proxy; BCE waits on hearing; union takes on airline deal
|
5/9/2008 | BK | S&P puts Biovail on watch
|
5/8/2008 | SS | Former Biovail CEO questions timing of new CEO's appointment, lump-sum payment to chairman
|
4/10/2008 | SS | Former Biovail CEO drops claim against company related to proxy solicitation
|
3/13/2008 | SS | Biovail founder, largest shareholder to propose changes to board
|
12/11/2007 | BKHY | S&P: Biovail unchanged
|
12/6/2007 | BKHY | S&P lowers Biovail
|
6/13/2007 | SS | Biovail CEO says company in strong position with healthy cash flows
|
2/28/2007 | HY | Biovail calls 7 7/8% notes due 2010
|
12/6/2006 | HY | Biovail plans redemption of all 7 7/8% notes due 2010
|
11/17/2006 | BKCVHY | Moody's ups Biovail view to stable
|
11/10/2006 | BT | Biovail rated at outperform by RBC
|
11/9/2006 | BT | Biovail reducing costs, increasing operations in anticipation of generic Wellbutrin XL entering market
|
11/8/2006 | BT | Biovail at outperform by RBC
|
10/5/2006 | BT | Biovail 'never better,' reports $600 million of cash on hand
|
9/26/2006 | BT | RBC puts Biovail at outperform
|
9/21/2006 | BKBTCVHY | Moody's revises ratings for nine U.S. pharma companies
|
8/24/2006 | BT | Biovail sues FDA over generic Wellbutrin bioequivalence
|
8/24/2006 | BT | Market Commentary: Biovail sues U.S. FDA; Dendreon's stock climbs after seeking application from FDA
|
8/10/2006 | BT | Biovail says it will keep off-patent products, use revenues to accelerate R&D in other programs
|
8/10/2006 | BT | Biovail gets outperform rating from RBC
|
8/8/2006 | BT | Biovail at outperform by RBC
|
8/2/2006 | BKBTCVHY | S&P: Biovail unchanged
|
8/2/2006 | BT | Biovail to release new guidance following denial of Wellbutrin XL patent-infringement suit
|
8/2/2006 | BT | RBC rates Biovail at outperform
|
8/2/2006 | BT | Market Commentary: Pozen pumped by partnership; Biovail battered by patent loss; Gene Logic gains on layoffs
|
7/31/2006 | BT | Biovail chairman's hearing on insider trading allegations set for Sept. 21
|
7/25/2006 | BT | Biovail rated at outperform by RBC
|
7/24/2006 | BT | Biovail, Athpharma terminate joint development agreement
|
7/21/2006 | BT | Biovail rated at outperform by RBC
|
6/16/2006 | BKBT | Biovail gets $250 million amended and renewed revolver
|
5/25/2006 | BTHY | Biovail tenders for $56.6 million of 7 7/8% notes
|
5/19/2006 | BT | Biovail to promote Novartis' Lescol products in Canada
|
5/11/2006 | BT | Biovail total revenues up 27% to $173.7 million
|
4/12/2006 | BT | Biovail launches Wellbutrin XL in Canada
|
3/24/2006 | BT | Credit Suisse maintains Biovail at neutral
|
3/7/2006 | BT | Biovail announces changes to organizational structure
|
2/23/2006 | BT | Market Commentary: Kos crashes on results, warning; GTC garroted by E.U. rejection; Nastech higher; Biovail mixed
|
2/22/2006 | BT | Biovail seeks $4.6 billion from 22 defendants in lawsuit alleging stock market manipulation
|
1/17/2006 | BT | Biovail receives approval for Wellbutrin XL depression drug in Canada
|
12/21/2005 | BT | Biovail says FDA approved oral-disintegrating citalopram tablets for depression
|
12/21/2005 | BT | Market Commentary: Biopure bleeds off 13% after deal; MGI rises 11%; Sinovac up 8%; Novavax plunges 14% post close
|
12/13/2005 | BT | Depomed withdraws lawsuit against Biovail as companies revise Glumetza agreement
|
12/1/2005 | BKHY | Moody's affirms Biovail
|
11/23/2005 | BT | Depomed, Biovail agree to temporary standstill on Glumetza lawsuit
|
11/15/2005 | BKBTHY | S&P: Biovail unaffected
|
11/15/2005 | BT | Biovail to spin off its off-patent products
|
11/15/2005 | BT | Citigroup reiterates Biovail at high risk buy rating
|
11/15/2005 | BT | Market Commentary: Allergan bid a wrinkle in Medicis merger with Inamed; Biovail off on spinoff plan; SkyePharma up
|
8/26/2005 | BKBTHY | S&P ups Biovail view to stable, rates loan BBB-
|
5/26/2005 | BK | Biovail renews $250 million credit facility
|
3/7/2005 | BKHY | S&P: Biovail unaffected
|
6/16/2004 | BKHY | Moody's confirms Biovail ratings
|
3/23/2004 | BK | Biovail renews $400 million revolver
|
3/9/2004 | BKHY | S&P: Biovail outlook negative
|
3/9/2004 | HY | Market Commentary: MGM Mirage, Corning, Amkor lead busy primary; Biovail off as agencies eye downgrade
|
3/8/2004 | BKHY | Moody's may cut Biovail rating
|
12/24/2003 | BK | Biovail extends loan to March 2004
|
12/23/2003 | HY | Market Commentary: Parmalat retreats further as woes grow; Rhodia up on debt deal; primary stilled
|
12/10/2003 | HY | Market Commentary: Blue Ridge deal, downsized THL/Simmons price; Collins & Aikman speeds upward
|
11/21/2003 | HY | Market Commentary: J. Ray McDermott sells 10-years; Hyundai shelved; Sbarro fall continues
|
11/6/2003 | HY | S&P cuts Biovail outlook
|
10/30/2003 | HY | Market Commentary: Silgan, O'Charley's price deals; Elan, Levi firmer, Biovail off on earnings; funds essentially flat
|
5/2/2002 | HY | Moody's downgrades Sealy Mattress' debt ratings
|
3/27/2002 | HY | Market Commentary: Adelphia falls but reaction muted; upsized Boyd Gaming trades higher in secondary
|
3/27/2002 | HY | UBS says Biovail 8% yield is lowest ever for B2 health care credit
|
3/26/2002 | HY | Moody's puts Pennzoil-Quaker State on upgrade review
|
3/26/2002 | HY | Pennzoil debt firmer on Shell acquisition bid; Crown Cork holds gains; Hockey Co. scores
|
3/25/2002 | HY | New Issue: Biovail eight-year notes upsized to $400 million, yield 8%
|
3/25/2002 | HY | S&P downgrades Calpine
|
3/25/2002 | HY | Market Commentary: Crown Cork boosted by buyout buzz; Calpine shrugs off S&P downgrade; upsized Biovail prices
|
3/22/2002 | HY | Biovail $275 million eight-year notes talk at 8%-81/4%, pricing Monday
|
3/19/2002 | HY | Market Commentary: XM Satellite Radio runs into static; Calpine powers up; Hovnanian brings new deal
|
3/19/2002 | HY | Biovail starts roadshow for $275 million eight-year notes Wednesday; via UBS Warburg
|
11/28/2001 | CV | Biovail redeems convertibles, almost all exchanged for stock
|
11/16/2001 | CV | Moody's downgrades XO
|
10/31/2001 | CV | S&P rates SuperValu convertible at BBB
|
10/30/2001 | CV | Tenders
|